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Abstract
Background: The pulmonary phenotype in cystic fibrosis (CF) is variable; thus, environmental and genetic factors likely
contribute to clinical heterogeneity. We hypothesized that genetically determined ABO histo-blood group antigen (ABH)
differences in glycosylation may lead to differences in microbial binding by airway mucus, and thus predispose to early lung
infection and more severe lung disease in a subset of patients with CF.
Methods and Principal Findings: Clinical information and DNA was collected on .800 patients with the DF508/DF508
genotype. Patients in the most severe and mildest quartiles for lung phenotype were enrolled. Blood samples underwent
lymphocyte transformation and DNA extraction using standard methods. PCR and sequencing were performed using
standard techniques to identify the 9 SNPs required to determine ABO blood type, and to identify the four SNPs that
account for 90–95% of Lewis status in Caucasians. Allele identification of the one nonsynonymous SNP in FUT2 that
accounts for .95% of the incidence of nonsecretor phenotype in Caucasians was completed using an ABI Taqman assay.
The overall prevalence of ABO types, and of FUT2 (secretor) and FUT 3 (Lewis) alleles was consistent with that found in the
Caucasian population. There was no difference in distribution of ABH type in the severe versus mild patients, or the age of
onset of Pseudomonas aeruginosa infection in the severe or mild groups. Multivariate analyses of other clinical phenotypes,
including gender, asthma, and meconium ileus demonstrated no differences between groups based on ABH type.
Conclusions and Significance: Polymorphisms in the genes encoding ABO blood type, secretor or Lewis genotypes were
not shown to associate with severity of CF lung disease, or age of onset of P. aeruginosa infection, nor was there any
association with other clinical phenotypes in a group of 808 patients homozygous for the DF508 mutation.
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Introduction
Cystic fibrosis (CF) is the most common life shortening genetic
disorder in Caucasians, and occurs in 1 in 3200 Caucasians in the
U.S. [1] Since the identification of the CF gene in 1989 [2], over
1500 mutations in the Cystic Fibrosis Transmembrane Conduc-
tance Regulator (CFTR) have been associated with CF. [3] The
most common mutation, DF508, occurs in ,70% of CFTR alleles.
[1] Although numerous mutations in the CF gene have been
described, there is little correlation between the specific mutation in
the CF gene and severity of pulmonary disease. Recent investiga-
tions have focused on the identification of other non-CF gene
variants that may affect the phenotype, i.e. ‘‘modifier genes.’’ [4,5]
Mutations in CFTR cause CF, and the initial pathophysiology
of the lung disease involves defective ion transport, dehydration of
the mucous layer, and reduced mucociliary and cough clearance.
[6] These abnormalities lead to chronic bacterial infection, which
is the key factor in the morbidity and mortality of CF lung disease
[7,8]; additionally, respiratory viral infections are associated with
exacerbation and progression of lung disease. [9,10]
Bacteria and viruses bind to mucins and the cellular glycocalyx
of airway epithelia based on their glycosylation patterns[11]; thus,
genetically based differences in patterns of glycosylation and
microbial binding may increase the likelihood of airway infection,
and contribute to progression of airway damage, and severity of
lung disease. One cause of variability in glycosylation of airway
PLoS ONE | www.plosone.org 1 January 2009 | Volume 4 | Issue 1 | e4270epithelia is inherited blood type, which reflects genetic-based
differences in glycosylation enzymes. The histo-blood group
antigens, ABO, H, and Lewis, are formed by the action of
glycosyltransferases to attach sugar molecules to disaccharide
precursors. (See Supplement Text S1 and Figure S1.) Addition of
fucose to these disaccharide precursors creates the H antigen, and
further modification to the H antigen by glycosyltransferases leads
to synthesis of the blood group antigens encoded by the ABO
(‘‘blood type’’) gene. The O allele does not produce an active
enzyme. [12]
Formation of other histo-blood group antigens is dependent on
fucosyltransferases. The FUT2 ‘‘secretor’’ gene encodes the
fucosyltransferase that synthesizes the H antigen. Loss-of-function
mutations in FUT2 (secretor gene) lead to an absence of ABH
antigens in the lung, saliva, and gut, resulting in the ‘‘non-
secretor’’ phenotype. Loss-of-function mutations in the FUT3
(Lewis) gene result in the Lewis negative phenotype. [11]
The ABO gene is highly polymorphic, which is thought to be
related to evolutionary changes for host-pathogen interactions, as
many pathogens utilize surface glycoproteins in host invasion. [11]
There is correlation with ABH status and infection with bacteria
and viruses; for example, numerous studies have shown that the
binding and infection of humans with noroviruses (previously
Norwalk virus,) is dependent on ABO and secretor phenotype.
[13,14] Furthermore, certain strains of S. aureus bind to the Lewis
antigen [15], and P. aeruginosa has a lectin, PA-IIL, that is fucose-
specific. [16] Thus, genetic-based differences in glycosylation that
determine blood type can also predispose to an increased
likelihood of bacterial and/or viral binding and infection in the
airways. Additionally, polymorphisms in the genes coding for the
ABH antigens are associated with airway diseases, including
COPD and asthma. [17,18,19]
We speculated that genetic predisposition to different patterns of
glycosylation in the ABH pathway would lead to early chronic
lung infection in CF, and therefore, more severe progression of
disease. We tested the genotype of key (ABH) glycosylation
enzymes in CF patients with ‘‘severe’’ versus ‘‘mild’’ lung disease,
and tested for associations with age of onset of infection with P.
aeruginosa.
Methods
Objectives
1) Establish ABO, FUT2 and FUT3 genotype for each subject
2) Determine whether differences in ABH type predict differ-
ences in lung phenotype.
We hypothesized that subjects with ABH types with more
glycosylation (i.e. blood groups A, and B, and secretor and Lewis
positive phenotypes) would be more likely to have severe lung
phenotype as a result of having an increased predisposition to early
viral/bacterial infection.
Participants
Patients with Cystic Fibrosis homozygous for the DF508 CF
gene mutation were enrolled from 44 sites (n=808 patients) as
previously published. [20] Patients were enrolled based on FEV1
values in the lowest quartile (‘‘severe;’’ n=263) or highest quartile
(‘‘mild;’’ n=545) for age. FEV1 data has been analyzed according
to biostatistical models based on longitudinal lung function (FEV1.)
This modeling has robust power to predict survival; hence the use
of multiple spirometric values is a strong surrogate for long-term
outcomes. [21]
Description of Procedures
Data Collection. Each patient received a unique identifier
code to maintain confidentiality. Source documents were collected
for pulmonary function tests, meconium ileus history and sputum
microbiology. Case report forms were used to collect information
about the presence of diabetes mellitus, steroid use, oral
hypoglycemic and insulin use.
Source of DNA. Whole blood in sodium citrate (for DNA
extraction) and heparinized (for lymphocyte transformation) tubes
was collected from all patients at the time of study enrollment.
DNA was extracted and stored using standard methodology in the
central molecular pathology facility at University of North
Carolina-Chapel Hill (UNC) Hospitals. DNA and transformed
lymphocytes were stored frozen in two different storage containers
at two separate sites with continuous monitoring.
ABO Genotyping. Sequence variation in 7 ABO alleles
accounts for .90% of the variants in white Europeans. [12]
Primers were designed to amplify three fragments from exons 6
and 7 containing the 9 SNPs (rs8176719, rs8176720, rs1053878,
rs7853989, rs8176740, rs8176741, rs8176742, rs816750,
rs8176472) necessary to identify blood type. (See Supplement
Text S1 and Table S1 for primer sequences.) PCR was performed
using standard techniques, and high throughput sequencing was
performed on an ABI PrismH 3730 Genetic Analyzer. Batch data
analysis was performed with SNP finding via the Polyphred
program. (See Supplement Text S1 and Table S2 for sequence
variation information used to construct ABO phenotype.)
FUT2 Genotyping. Loss of function mutations in FUT2
(non-secretor) occur in 20% of European-derived Caucasians. In
Caucasians, one nonsynonymous SNP in FUT2 (G428A,
rs601338) accounts for .95% of the incidence of nonsecretor
phenotype. [22] Allele identification was performed using an ABI
Taqman assay on an ABI PrismH 7700HT/7900HT Sequence
Detection System.
FUT3 Genotyping. Loss of function mutations in FUT3
(Lewis negative) occur in 10% of European-derived Caucasians.
SNPs in four positions (T59G, rs28362459; T202C, rs812936;
C314T, rs778986; and T1067A, rs3894326) account for 90–95%
of Lewis status in Caucasians. [23] Primers were designed for PCR
amplification, and sequencing of the FUT3 gene was performed
on an ABI PrismH 3130xl/310 Genetic Analyzer. [24,25]
Acquisition of P. aeruginosa. In addition to lung function
data, all available CFF registry data on study subjects that related
to respiratory tract (oropharyngeal and sputum) cultures was
acquired. Age of onset of persistent P. aeruginosa infection for all
patients was established with available culture data (n=674), and
defined as the first age at which P. aeruginosa was present in
respiratory cultures in two consecutive, or two out of three years.
Ethics. This study was approved by Institutional Review
Boards at all participating institutions. Each participant provided
written informed consent prior to study participation. The study is
registered in the ClinicalTrials.gov database: NCT00037765.
Statistical Methods. To test for associations between
severity of lung disease, key clinical phenotypes, and
polymorphisms in ABH genotypes, Fisher’s exact test was used.
All tests were two-sided. To investigate the effect of blood group
alleles (ABO genotype, nonsecretor phenotype, and FUT3
genotypes producing Lewis negative phenotypes) on CF lung
severity risk, we performed multiple logistic regression analyses to
predict severity status. The number of A and B antigen alleles was
included in an additive model on the log-odds of severe lung status,
as well as the FUT2 and FUT3 genotypes, and terms to account
for possible interaction between the genes. In addition, the
following predictors were used in the model: gender, meconium
ABH Gene Polymorphisms in CF
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shown to be associated with severe lung disease.) In order to
determine whether ABH type influenced the age of acquisition of
P. aeruginosa, Kaplan-Meier analysis was performed using
SigmaStatH software. ABO type, and secretor and Lewis status
were evaluated in the mild versus severe groups. Additionally, to
address the possibility of age confounding the analysis of P.
aeruginosa acquisition, ABH types were also analyzed in the severe
group versus the group of mild patients who were aged 15–
28 years (‘‘young milds,’’) and interactions among the three ABH
types were analyzed. Allelic comparison that yielded a statistical
significance of #0.05 was considered significant. Unadjusted p-
values are reported.
Results
Characteristics of the patients
As previously reported, pulmonary and nutrition characteristics
of the patients classified as severe (n=263) were markedly different
than that of patients classified as mild (n=545.) [20] Although the
mean age of the patients in the mild group was 28.6 6 9.7 years
compared to 16.2 6 4.2 years in the severe group, FEV1 was more
than 25% higher and body mass index percentile was 24% higher
in the patients in the mild group versus those in the severe group
(p,0.001). Gender, prevalence of diabetes mellitus (adjusted for
age), and asthma were similar between patients in the mild and
severe groups. [20]
ABO genotype
ABO genotype was successfully determined for 778 patients.
ABO allele frequencies, and resultant ABO blood groups were
consistent with the reported prevalence in the Caucasian popula-
tion. [26,27] (See Supplement Text S1 and Table S3.) We saw no
significant difference in blood type distribution between mild and
severe patients by Fisher exact test. (p=0.446). (Table 1) We also
saw no significant associations when ABO allele distribution was
analyzed in the following subgroups: males and females, patients
with and without asthma, and patients with and without history of
meconium ileus. (Data not shown.)
FUT2 genotype
FUT2 (‘‘secretor/nonsecretor’’) alleles for SNP G428A
(rs601338) were successfully determined in 806 patients. The
distribution of alleles was consistent with that found in the
Caucasian population. [27] There was no significant difference in
secretor status distribution between mild and severe patients by
Fisher exact test (p=0.569). (Table 2) Subgroup analysis by
gender, asthma and meconium ileus status did not reveal any
associations. (Table 2)
FUT3 genotype
Four SNPs account for 90–95% of Lewis status in Caucasians.
[23] FUT 3 alleles were successfully determined at these four loci
for 707 patients. There was no significant difference for individual
SNPs between mild versus severe lung disease patients, nor by
gender, meconium ileus or asthma status by Fisher exact test. (See
Table 2.) Orntoft et al correlated FUT3 gene mutations with
enzyme activity and circulating levels of sialyl-Lewis a [28];
therefore, the SNPs were analyzed in groups consistent with Lewis
negative or positive phenotypes, but no significant differences were
observed. (Data not shown.) [23]
ABH Type
We anticipated that the A, B or AB blood group, secretor (FUT2)
and Lewis positive (FUT3) genotypes would be found in higher
prevalence in patients with severe lung phenotype, because
genotypes associated with functional fucosyltransferases for synthe-
sis of pertinent glycoproteins have been shown to be associated with
increased propensity towards infection with P. aeruginosa, H.
influenzae and S. aureus. [15,29] Conversely, we thought that O
blood group, non-secretor and Lewis negative genotypes (genotypes
that lack or produce nonfunctional fucosyltransferases) would have
higher prevalence in patients with mild phenotypes, reflecting a
reduced risk of infection. In order to evaluate the effect of ABH type
(A, B, AB, or O blood type, secretor status, and Lewis status) on risk
for severe lung disease, multiple logistic regression was performed
using the severity phenotype as a response, and the ABH type
variablesaspredictors.NeithermaineffectsnorinteractionsofABH
genotypes achieved marginal significance at level alpha=0.10. (See
Supplement Text S1 and Table S4.)
Acquisition of P. aeruginosa and ABH Type
By age 18, up to 80% of CF patients are colonized with P.
aeruginosa. [7] Thus, in our population of patients, there was no
significant difference between P. aeruginosa colonization in the mild
versus the severe groups at the age of enrollment (mean age
28.669.7 years and 16.264.1 years, respectively.) In order to
determine if ABH status was associated with early infection with P.
aeruginosa, data from the national CFF Registrywas used to determine
age of first acquisition of P. aeruginosa for each patient (as defined in
Methods.) So that the question could be examined in a groups of
patients that were similar in age for this comparison, data from both
the entire mild group, and from a subset of the mild group (‘‘young
milds,’’ age 15–28 years with a mean age of 20.964.0 years) was
used. A clear distinction was noted in the age of onset for persistent P.
aeruginosa infection (age 6.9 years in the severe group, n=194 versus
age12.4 years in the young mild group, n=224 p,0.0001) [30]
Completedata (at least 3 yearsof P.aeruginosaculturedata available to
define persistent infection, and information for at least one of the
three ABH genotypes) was available on 661 patients. Associations
between ABO, secretor and Lewis phenotypes and P. aeruginosa
acquisition were analyzed by Kaplan-Meir plots for patients in the
severe group, for patients in the entire mild group, and for patients in
the young mild group. No significant differences for ABO blood
group, secretor versus non-secretor status, or Lewis positive versus
Lewis negative status were observed within groups. Furthermore, no
significant differences were seen between patients in the severe group
compared to those in the mild group nor in the young mild group
based on ABH status. (Figure 1; for simplicity, combined data for
patients in the severe and young mild groups is shown. Individual
Table 1. Prevalence of ABO blood types in severe and mild
patient groups.
Blood type Severe Group Mild Group
O 127 (50.8%) 243 (46.2%)
B 21 (8.3%) 62 (11.8%)
A 94 (37.3%) 202 (38.4%)
AB 9 (3.6%) 19 (3.6%)
252 526
ABO allele frequencies and resultant ABO phenotypes were consistent with
known prevalence in the Caucasian population. [26] There is no significant
difference in blood type distribution amongst mild and severe patients, or in
any subgroup analysis (see Text S1) by Fisher exact test. (n=778, p=0.446)
doi:10.1371/journal.pone.0004270.t001
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Text S1 and Figure S2.)
Discussion
Although a great deal is known about the pathophysiology of
CF lung disease, and more than 1500 CF mutations have been
described [17], predictable correlation between CFTR genotype
and lung phenotype has not been established. [31] Furthermore, it
is known that patients with the same CF gene mutations can have
highly variable outcomes. [32] Two studies of CF twins and
siblings have shown that most of the disease variation reflects
genetic rather than environmental influences [33,34]; thus,
multiple studies are investigating what non-CF genes may play a
role in CF phenotype. [20]
We chose to evaluate the ABH genes as candidates for modifiers
of CF lung disease severity because the role postulated for these
polymorphic genes coding for the ABH antigens is thought to be
related to host-pathogen interactions; specifically, many pathogens
utilize surface glycoproteins in host invasion. Numerous studies
have shownthatthe bindingand infectionofhumanswith microbial
organisms is dependent on ABH status; for example, noroviruses
(previously Norwalk virus,) certain strains of S. aureus, H. influenzae,
and P. aeruginosa have this capability. [13,14] Polymorphisms in the
genes coding for the ABH antigens are also known to be associated
with various disease states, including pulmonary disease. [11]
Patients with COPD who are nonsecretors had significantly lower
mean FEV1/FVC values than secretors, suggesting that the
presence of ABH antigens in respiratory epithelium may be
protective in COPD. [17] Similarly, Lewis negative or nonsecretor
status was significantly associated with lower lung function, and
higher prevalence of wheezing and asthma, in blood group O
adults. [18] The association between blood group O/nonsecretor
genotype and asthma has also been demonstrated in children.
[19,34] One small study was performed in fifty patients with CF to
evaluatewhethersecretorstatuswasa riskfactorforclinicalstatusor
P. aeruginosa or S. aureus colonization. The study found no correlation
between secretor status and the clinical variables examined;
however, it may have been significantly underpowered to detect a
difference with only 17 patients in the nonsecretor group. [35]
Based on previous studies demonstrating an association between
ABH genotype and predisposition to infection and lung disease
[36], we hypothesized that ABH type might affect lung severity in
CF, and genotyped approximately 800 CF patients for ABH type.
Although the whole genome scan approach will be used in future
genetic modifier studies, the candidate gene approach was chosen
to test our hypothesis as only two of the relevant ABH SNPs are
included on current SNP-based whole genome platforms.
We examined the ABO, secretor and Lewis status individually
in the severe versus mild CF lung disease groups, and found no
difference in prevalence of each ABH type between the two
groups.
The knowledge that lung disease severity may result from a
multitude of other genetic and environmental factors also lead us
to hypothesize that more specific phenotypes should be examined
for association with ABH genotype, such as female gender, which
is associated with worse outcome in CF. [37] Therefore, we
evaluated the prevalence of ABH genotypes in males versus
females, but no association was found in our CF population.
Although approximately 80% of patients develop chronic
Pseudomonal infection by early adulthood, the age of acquisition of
P. aeruginosa is variable. [8] Based on previous studies demonstrating
increased susceptibility to P. aeruginosa based on ABH group [16], and
increased affinity of P. aeruginosa for CF respiratory and salivary
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in prevalence of the ABH antigens amongst those patients with earlier
colonization with P. aeruginosa. However, there was no difference in
prevalence of ABO, secretor or Lewis genotypes associated with age
of onset of persistent P. aeruginosa whether we looked at all patients, or
restricted our analysis to the severe group or to the mild group.
Another phenotype considered was that of meconium ileus (MI).
It is known that only 15–20% of CF patients, regardless of CF gene
mutation, develop MI. Previous studies of ileal mucus in CF
neonates with MI have demonstrated increased fucosylation.
[42,43] CF gene knockout mice, whose main pathology is intestinal
mucous obstruction, have increased fucosylation and increased
FUT2 expression.[44] In a small study of homo- and heterozygous
DF508 patients, presence of both functional secretor and Lewis
genes was associated with meconium ileus. [45] These studies lead
us to hypothesize that MI in CF patients may be related to
glycosylation patterns/ABH status; however, no difference in
prevalence of ABH genotypes was found between the two groups.
Because there are only 129 patients in the MI group, this evaluation
may be under powered to detect a difference.
Limitations
Bacterial colonization and inflammation may appear very early
in CF lung disease [34], and prospective cultures were not
available; we recognize the limitation of data collected retrospec-
tively for P. aeruginosa acquisition and infection. However, we were
able to collect culture data on more than 60% of these patients by
age 8 years; 73% of the patients with mild disease and 60% of
patients with severe disease were culture negative for P. aeruginosa
at the time of first available culture. Thus, our sample should be
adequate to answer the question. However, if ABH genotypes
predispose to early bacterial or viral infection, it is possible that we
were unable to demonstrate this finding in our group of older
children and adults. To definitively determine if there is an effect
of differences in ABH genotype on early acquisition of infection
and subsequent lung health in CF, it would be necessary to
prospectively study this question.
In general, the loss of some patients from an original birth cohort
is a limitation to study designs examining variants in severe versus
mild forms of the disease. However, according to CF registry data,
for the cohort we examined, only 10% have died by age 16 years,
thus, there were relatively few deaths in our cohort. Additionally,
the patients in our cohort classified as having severe lung disease are
still in the worst 25
th percentile for their birth cohort, and the
patients with mild disease are in the upper 25
th percentile of their
birth cohort. The validity of these concepts has previously been
demonstrated; we reported that TGFB genotype is associated with
disease severity, and this finding has been replicated in two
additional cohorts. [20,46] Thus, while death of the most severe
patients could have potentially influenced the outcome of this study
because of the extremes of phenotype design, we do not believe that
limitation is a critical factor in the findings reported here.
In conclusion, there is a clear association between the age of
onset of chronic P. aeruginosa infection and the severity of lung
Figure 1. Association between age of onset of persistent P. aeruginosa infection and ABH type. Kaplan-Meir curves were generated
(includes exit censoring) to test associations between ABH and age of onset of P. aeruginosa infection in the respiratory tract for patients with mild
and severe disease. (For simplicity, figures show the proportion of infected patients in the combined group of young mild and severe patients for
whom culture and ABH genotype data was available.) A) ABO blood group, B) Secretor phenotype and C) Lewis phenotype. No significant differences
were seen.
doi:10.1371/journal.pone.0004270.g001
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genotype. We found no association between ABO blood group, or
secretor or Lewis status with lung disease severity or P. aeruginosa
infection status in a large group of CF patients homozygous for the
DF508 mutation. Nor did we find an association between ABH
genotype and gender, asthma or meconium ileus in this patient
population. This targeted study has generated important ‘‘nega-
tive’’ data regarding modifier genes in CF, which is not possible
through SNP-based platforms (e.g. Ilumina 550K chip) because
these platforms do not test for all of the pertinent SNPs necessary
to establish ABO, Secretor and Lewis status.
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0004270.s001 (0.07 MB
DOC)
Figure S1 Major pathways of synthesis of the ABH and Lewis
antigens (Adapted with permission.) [5] Type I is antigen
precursor of ABH antigens in secretions. Le-Lewis positive and
le=Lewis negative. See text for more detail. Lewis a/x denotes
addition to Type 1 or Type 2 disaccharide precursor. Lewis b/y
denotes addition to H antigen derived from Type 1 or Type 2
disaccharide precursor.
Found at: doi:10.1371/journal.pone.0004270.s002 (0.13 MB
PDF)
Figure S2 Association between age of onset of persistent P.
aeruginosa infection and ABH type. Kaplan-Meir curves were
generated (includes exit censoring) to test associations between
ABH and age of onset of P. aeruginosa infection in the respiratory
tract for patients with mild and severe disease. Figures show the
proportion of infected patients in the young mild and severe
patients for whom culture and ABH genotype data was available.
A) ABO blood group in patients with severe disease, B) ABO blood
group in young patients with mild disease, C) Secretor phenotype
in patients with severe disease D) Secretor phenotype in young
patients with mild disease E) Lewis phenotype in patients with
severe disease, F) Lewis phenotype in young patients with mild
disease. A marginally significant p-value (p=0.032) was demon-
strated in secretor status in patients in the severe group. No other
significant differences were seen by Log-Rank test. S-Secretor, NS-
Nonsecretor
Found at: doi:10.1371/journal.pone.0004270.s003 (3.82 MB TIF)
Table S1 PCR fragments and primers for ABO genotyping.
Primers were designed to amplify three fragments from exons 6
and 7 containing the 9 SNPs (rs8176719, rs8176720, rs1053878,
rs7853989, rs8176740, rs8176741, rs8176742, rs816750,
rs8176472) necessary to identify blood type.
Found at: doi:10.1371/journal.pone.0004270.s004 (0.02 MB
DOC)
Table S2 Sequence variations in the 7 most common ABO
alleles. Base changes resulting in sequence variation. Changes are
shown with reference to A1. This research was originally published
in (3)  the American Society of Hematology.
Found at: doi:10.1371/journal.pone.0004270.s005 (0.03 MB
DOC)
Table S3 Reported incidence of ABO, secretor and Lewis
phenotypes in the N=692. The reported incidence of ABO,
secretor and Lewis phenotypes is shown in black. [7] Based on our
ABH genotyping, the percentage of GMS patients in each
category is shown in italics.
Found at: doi:10.1371/journal.pone.0004270.s006 (0.03 MB
DOC)
Table S4 Multivariate regression analysis. To investigate the
effect of blood group alleles (ABO genotype, nonsecretor
phenotype, and FUT3 genotypes producing Lewis negative
phenotypes) on CF lung severity risk, we performed multiple
logistic regression analyses to predict severity status. As previously
reported [1], there was a highly statistically significant correlation
with the TGF-b codon 10 CC genotype, and a moderately
significant association with meconium ileus status. No other
variables achieved marginal significance at level alpha=0.10,
including main effects and interactions of ABH genotypes.
Found at: doi:10.1371/journal.pone.0004270.s007 (0.04 MB
DOC)
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